TABLE 1.
Demographics and clinical data from 30 patients with CIDP
| Variable | Median (IQR) |
|---|---|
| Age (years) | 66.0 (48.0‐73.0) |
| Sex, M:F (n) | 22:8 |
| Age at onset (years) | 47.5 (34.0‐58.0) |
| Time since onset of CIDP (years) | 14.6 (11.5‐19.0) |
| Time since first contact to neurologist (years) | 14.0 (11.0‐16.0) |
| Duration of CIDP until treatment initiation (years) | 0.75 (0.25‐1.5) |
| Interval between initial and follow‐up assessments (years) | 13.4 (10.9‐15.8) |
| Acute, GBS‐like onset (n) | 5 |
| Walking status at initial visit (n) | |
| Walking independently | 22 |
| Walking with aids | 3 |
| No ambulation | 5 |
| Walking status at follow‐up (n) | |
| Walking independently | 28 |
| Walking with aids | 1 |
| No ambulation | 1 |
| I‐RODS score at follow‐up (a.u.) | 73.0 (67.0‐88.0) |
| NIS score at follow‐up (a.u.) | 23.0 (15.0‐30.5) |
| Isokinetic strength, normalized (%) | 56.1 (44.4‐68.7) |
| Current treatment (n) | |
| IgG | 14 |
| Azathioprine | 1 |
| Rituximab | 1 |
| Prednisolone | 1 |
| No treatment | 15 |
| Combined axonal Z score | |
| Initial | −3.6 (−6.3 to −2.3) |
| Follow‐up a | −3.2 (−4.8 to −1.4) |
| Combined demyelination Z score | |
| Initial | −4.1 (−4.8 to −2.5) |
| Follow‐up b | −3.0 (−4.0 to −1.1) |
Abbreviations: CIDP, chronic inflammatory demyelinating polyneuropathy; F, female; GBS, Guillain‐Barré syndrome; IgG, immunoglobulin G; I‐RODS, Inflammatory Rasch‐built Overall Disability Scale; IQR, interquartile range; M, male; NIS, neuropathy impairment score.
a
P = .1.
b
P = .02.